Tuesday, April 15, 2014 - 08:01
Position Title: Public Policy Manager
Location: Washington, DC area
Reports to: Executive Director
Posted: April 15, 2014
Wednesday, April 9, 2014 - 06:48
Dr. Ron Valdiserri and Corinna Dan will provide an overview of the updated Action Plan for the Prevention, Care and Treatment of Viral Hepatitis (2014-2016) and highlights from the April 3rd, 2014 launch. They will also discuss how community organizations, individuals, and state/local health departments can interact with the plan to advance the fight against the viral hepatitis epidemic. There will be time for questions and comments.
Thursday, April 3, 2014 - 08:15
We are excited to announce a survey to inform the first program work of NVHR!
Monday, March 31, 2014 - 08:11
Urge Your Senator To Sign Important Appropriations Letter
Senator Jeff Merkley (D-OR) is asking all Senators to sign an important letter supporting increased funding for viral hepatitis programs in the Fiscal Year 2015 appropriations bill (see text of letter below and in attached document).
Tuesday, March 4, 2014 - 14:53
CMS has released its National Coverage Determination draft memo that proposes Medicare coverage of hepatitis C testing for Medicare beneficiaries at high risk and one time testing of everyone born between 1945 and 1965. The memo was posted today and there is a public comment period through April 3, 2014. NVHR will be pulling together a call soon to discuss public comment strategies and to prepare for implementation/education. Another great victory for us!
Tuesday, February 25, 2014 - 09:09
Read NVHR's letter sent to State Medicaid Directors
Friday, February 14, 2014 - 15:45
Attached a press release from WHO, from last week, which raises liver cancer up to the 2nd leading cause of cancer death worldwide (after lung cancer). It was previously 3rd. This is very compelling evidence to use as we strive to include liver cancer more in our messaging and talks
with our federal/national partners.
Monday, February 3, 2014 - 14:31
Sample letter for medical providers regarding for insurance company denial of treatment using two new FDA approved drugs to treat chronic hepatitis C, Olysio (simeprevir) and Sovaldi (sofosbuvir)
Monday, February 3, 2014 - 14:28
Read NVHR's letter to medical providers regarding the appeals process to appeal insurance company denial of treatment using two new FDA approved drugs to treat chronic hepatitis C, Olysio (simeprevir) and Sovaldi (sofosbuvir)
Friday, January 31, 2014 - 10:38